Trials / No Longer Available
No Longer AvailableNCT01533506
Stiripentol in Dravet Syndrome
Compassionate Use of Stiripentol in Intractable Epilepsy Due to Dravet Syndrome
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- Female
- Age
- 11 Years
- Healthy volunteers
- Not accepted
Summary
The patient has failed all other available agents and has intractable epilepsy due to Dravet Syndrome. Stiripentol is highly efficacious in Dravet Syndrome. The overall goals of therapy with Stiripentol are primarily to significantly reduce the frequency and severity of seizures.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | stiripentol | Stiripentol up to 30 mg/kg/day to control seizures |
Timeline
- Start date
- 2012-02-01
- Primary completion
- 2013-02-01
- Completion
- 2013-02-01
- First posted
- 2012-02-15
- Last updated
- 2013-02-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01533506. Inclusion in this directory is not an endorsement.